Stocks to Buy

Whether you are a novice who just opened your first 401k or you are a seasoned investor, you have to spend countless hours researching stocks to buy. Who has that kind of time? We do. Powered by a diverse group of perspectives formed from dozens of analysts, advisors and strategists, our stories digest the day’s biggest headlines to uncover which stocks you should buy.

10 Best “Strong Buy” Stocks — LAD LL FLT and more

This week, these ten stocks, all currently earning A's ("strong buy") on Portfolio Grader, have the best year-to-date performance. Since the beginning of the year, the Nasdaq is up 10.9%, the Dow rose 13.2%, and the S&P has increased 12.1%.

3 Ways Red-Hot Tesla Could Go From Here

After a 300% move in 12 months, it's a good time to explore which way Tesla Motors stock might turn next.

5 Biotechnology Stocks to Buy Now

The grades of five Biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.

Get Ready for the Next Texas Oil Rush

A little-known field in West Texas called the Cline Shale be the next hot ticket for energy producers, and the next big play for energy investors.

4 Packaged Foods Stocks to Buy Now

Four Packaged Foods stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an "A" ("strong buy") or "B" overall ("buy").

5 Stocks With Prime Earnings Momentum — KNSY MIL ALJ AMED URS

This week, these five stocks have the best ratings in Earnings Momentum, one of the eight Fundamental Categories on Portfolio Grader.

Pharmacy Wars: Walgreens vs. CVS

The two largest U.S. pharmacy chains have both come roaring back, but which one -- CVS or Walgreens -- is the better bet for investors? Let's break it down.

22 Commercial Banking Stocks to Buy Now

The grades of 22 Commercial Banking stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").

3 Short Squeeze Candidates for July

A new wave of cash flow into stocks from the flagging bond market is pressuring short sellers -- especially for these three names.

Supercharge Your Analysis With Insider Insights

I'm a numbers guy through and through ... but that doesn't mean I'm blind to other positive developments. And an insider buying up shares of his company's stock is one of the very best.

3 Building Products Stocks to Buy Now

The grades of three Building Products stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").

5 Stocks With Strong Cash Flow — KT XIN ZA MIL GSL

This week, these five stocks have the best ratings in Cash Flow, one of the eight Fundamental Categories on Portfolio Grader.

Which Airline Stocks Will Soar Short-Term?

Not all U.S. airlines are created equal, and three key factors will likely determine which airlines are poised to soar -- or stall -- in the near-term.

Buy These Rail Players on a Dip

A deadly derailment in Quebec has many questioning (and fighting against) the future of crude-by-rail. But these rail companies are doing too well to disappear.

5 Stocks With Strong Earnings Growth — MIL MA MXWL AEGN JNJ

This week, these five stocks have the best ratings in Earnings Growth, one of the eight Fundamental Categories on Portfolio Grader.

5 Best Sectors to Watch This Week

This week, Household Products, Water Utilities, Leisure Goods, Infrastructure, and Beverages are the best sectors on the Portfolio Grader database.

5 Stocks With Prime Operating Margin Growth — IDT MX CALL AHS ICA

This week, these five stocks have the best ratings in Operating Margin Growth, one of the eight Fundamental Categories on Portfolio Grader.

5 Stocks With Great Sales Growth — IDCC INSY AGM HGSH ESGR

This week, these five stocks have the best ratings in Sales Growth, one of the eight Fundamental Categories on Portfolio Grader.

Rest Easier With This Pair of Fundamentally Sound Biotechs

Biotechs can be lucrative but risky investments -- improve your chances by focusing on biotechs with quality fundamentals.